Evaluation of changes in instrumental and biochemical markers of heart diseases in patients with bladder cancer under the condition of intravenous and intravesical doxorubicin administration

  • N. L. Hodovan National Pirogov Memorial Medical University, Vinnytsya, Ukraine
Keywords: bladder cancer, chemotherapy, myocardial destruction, doxorubicin.


Due to the constant increase in morbidity and mortality, bladder cancer remains a pressing problem in modern medicine. Despite the success of chemotherapy, chemotherapy physicians around the world have been concerned about the safety of these drugs for many years. Doxorubicin has been used as an antitumor drug for more than 40 years in various hematological and solid malignancies, however, its toxic effects when administered intravenously to vital organs and organ systems, including the heart, require further research. The aim of our study was to evaluate the manifestations and progression of cardiotoxicity in patients with bladder cancer with systemic and intravesical administration of doxorubicin. The study included 96 patients who were divided into three groups: the first group or the control group – patients who had a confirmed diagnosis of first stage bladder cancer, were treated surgically and did not receive doxorubicin; the second group – patients who, in addition to surgical treatment, received doxorubicin systemically (intravenously) in a therapeutic dose; the third group – patients who received doxorubicin at a dose of 50 mg, locally, by instillation of the drug into the bladder cavity, after prior catheterization with an elastic catheter. ECG data and biochemical markers of myocardial destruction before and after chemotherapy were studied. The study found that systemic serial administration of doxorubicin to patients with bladder cancer causes significant changes in the myocardium after the first course of chemotherapy. A single intravesical instillation of doxorubicin does not cause changes in laboratory and instrumental heart rate.


[1] Babjuk, M., Burger, M., Compérat, E. M., Gontero, P., Mostafid, A. H., Palou, J., … & Soukup, V. (2019). European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. European urology, 76(5), 639-657. doi: 10.1016/j.eururo.2019.08.016
[2] De Angelis, R., Sant, M., Coleman, M. P., Francisci, S., Baili, P., Pierannunzio, D., … & EUROCARE-5 Working Group. (2014). Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study. The Lancet. Oncology, 15(1), 23-34. doi: 10.1016/S1470-2045(13)70546-1
[3] Diamanti, J., Mezzetti, B., Giampieri, F., Alvarez-Suarez, J. M., Quiles, J. L., Gonzalez-Alonso, A., … & Battino, M. (2014). Doxorubicin-induced oxidative stress in rats is efficiently counteracted by dietary anthocyanin differently enriched strawberry (Fragaria × ananassa Duch.). Journal of agricultural and food chemistry, 62(18), 3935-3943. doi: 10.1021/jf405721d
[4] Ferlay, J., Steliarova-Foucher, E., Lortet-Tieulent, J., Rosso, S., Coebergh, J. W., Comber, H., … & Bray, F. (2013). Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. European journal of cancer (Oxford, England : 1990), 49(6), 1374-1403. doi: 10.1016/j.ejca.2012.12.027
[5] Kalyanaraman, B. (2020). Teaching the basics of the mechanism of doxorubicin-induced cardiotoxicity: Have we been barking up the wrong tree?. Redox biology, 29, 101394. doi: 10.1016/j.redox.2019.101394
[6] Lehmann, L. H., & Fröhling, S. (2020). Mechanismen der Kardiotoxizität onkologischer Therapien [Mechanisms of cardiotoxicity of oncological therapies]. Der Internist, 61(11), 1132-1139. doi: 10.1007/s00108-020-00881-2
[7] Machan, L., Burt, H. M., & Hunter, W. L. (1997). Local delivery of chemotherapy: a supplement to existing cancer treatments. A case for surgical pastes and coated stents. Advanced drug delivery reviews, 26(2-3), 199-207. doi: 10.1016/s0169-409x(97)00035-5
[8] Mandziuk, S., Gieroba, R., Korga, A., Matysiak, W., Jodlowska-Jedrych, B., Burdan, F., … & Dudka, J. (2015). The differential effects of green tea on dose-dependent doxorubicin toxicity. Food & nutrition research, 59, 29754. doi: 10.3402/fnr.v59.29754
[9] Natsionalnyi instytut raku. (2020). Rak v Ukraini: Biuleten natsionalnoho kantser reiestru Ukrainy № 21 (21st ed.).
[10] Palmer, A., Mason, G. G., Paramio, J. M., Knecht, E., & Rivett, A. J. (1994). Changes in proteasome localization during the cell cycle. European journal of cell biology, 64(1), 163-175.
[11] Pugazhendhi, A., Edison, T., Velmurugan, B. K., Jacob, J. A., & Karuppusamy, I. (2018). Toxicity of Doxorubicin (Dox) to different experimental organ systems. Life sciences, 200, 26-30. doi: 10.1016/j.lfs.2018.03.023
[12] Rivett, A. J., Palmer, A., & Knecht, E. (1992). Electron microscopic localization of the multicatalytic proteinase complex in rat liver and in cultured cells. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society, 40(8), 1165-1172. doi: 10.1177/40.8.1619280
[13] Schmidt, S., Kunath, F., Coles, B., Draeger, D. L., Krabbe, L. M., Dersch, R., … & Meerpohl, J. J. (2020). Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer. The Cochrane database of systematic reviews, 1(1), CD011935. doi: 10.1002/14651858.CD011935.pub2
[14] Siegel, R. L., Miller, K. D., & Jemal, A. (2018). Cancer statistics, 2018. CA: a cancer journal for clinicians, 68(1), 7-30. doi: 10.3322/caac.21442
[15] Sun, X. P., Wan, L. L., Yang, Q. J., Huo, Y., Han, Y. L., & Guo, C. (2017). Scutellarin protects against doxorubicin-induced acute cardiotoxicity and regulates its accumulation in the heart. Archives of pharmacal research, 40(7), 875-883. doi: 10.1007/s12272-017-0907-0
[16] Tan, C., Tasaka, H., Yu, K. P., Murphy, M. L., & Karnofsky, D. A. (1967). Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer, 20(3), 333-353. doi: 10.1002/1097-0142(1967)20:3<333::aid-cncr2820200302>3.0.co;2-k
[17] van der Zanden, S. Y., Qiao, X., & Neefjes, J. (2021). New insights into the activities and toxicities of the old anticancer drug doxorubicin. The FEBS journal, 288(21), 6095-6111. doi: 10.1111/febs.15583
[18] Wenningmann, N., Knapp, M., Ande, A., Vaidya, T. R., & Ait-Oudhia, S. (2019). Insights into Doxorubicin-induced Cardiotoxicity: Molecular Mechanisms, Preventive Strategies, and Early Monitoring. Molecular pharmacology, 96(2), 219-232. doi: 10.1124/mol.119.115725
[19] Xing, M., Yan, F., Yu, S., & Shen, P. (2015). Efficacy and Cardiotoxicity of Liposomal Doxorubicin-Based Chemotherapy in Advanced Breast Cancer: A Meta-Analysis of Ten Randomized Controlled Trials. PloS one, 10(7), e0133569. doi: 10.1371/journal.pone.0133569
[20] Zhang, D., Yao, L., Yu, S., Cheng, Y., Jiang, J., Ma, Q., & Yan, Z. (2020). Safety and efficacy of en bloc transurethral resection versus conventional transurethral resection for primary nonmuscle-invasive bladder cancer: a meta-analysis. World journal of surgical oncology, 18(1), 4. doi: 10.1186/s12957-019-1776-4
[21] Zhao, L., & Zhang, B. (2017). Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes. Scientific reports, 7, 44735. doi: 10.1038/srep44735
[22] Zhou, Z., Zhao, S., Lu, Y., Wu, J., Li, Y., Gao, Z., … & Cui, Y. (2019). Meta-analysis of efficacy and safety of continuous saline bladder irrigation compared with intravesical chemotherapy after transurethral resection of bladder tumors. World journal of urology, 37(6), 1075-1084. doi: 10.1007/s00345-019-02628-7
How to Cite
Hodovan, N. L. (2021). Evaluation of changes in instrumental and biochemical markers of heart diseases in patients with bladder cancer under the condition of intravenous and intravesical doxorubicin administration. Biomedical and Biosocial Anthropology, (43), 40-44. https://doi.org/10.31393/bba43-2021-07